# Recovery & Tissue Repair Peptide FAQ — BPC-157, GHK-Cu, GLOW, Wolverine — RegenLife Peptides

> Frequently asked questions about four Recovery & Tissue Repair research peptides — BPC-157, GHK-Cu, GLOW, and Wolverine — answered from the peer-reviewed and preclinical literature, with citations.

Direct, citation-anchored answers to the questions readers most often bring to these four tissue-repair research peptides.

## What does BPC-157 do in the body?

BPC-157 is a synthetic pentadecapeptide studied mainly in animal models for angiogenesis (new blood-vessel growth), gastric-mucosa protection, and connective-tissue repair. Its best-characterized pathway is up-regulation of the VEGFR2 receptor and downstream VEGFR2-Akt-eNOS signaling, which increased vessel density and blood-flow recovery in ischemic muscle in rodent studies [4]. In Wistar rats it reduced gastric ulcer area and accelerated healing [5], and in a transected rat Achilles tendon model it improved biomechanical and functional recovery [6]. A first-in-human safety pilot found intravenous BPC-157 up to 20 mg well tolerated in two healthy adults with no measurable changes in cardiac, hepatic, renal, thyroid, or glucose biomarkers [1] — a safety signal, not an efficacy finding, and one of only three human studies that exist [2].

## Is BPC-157 a growth hormone?

No. BPC-157 is not a growth hormone and does not act through the growth-hormone axis in the way that term usually implies. In cultured tendon fibroblasts it has been reported to sensitize cells to growth-hormone-receptor signaling — meaning it may make existing growth-hormone signaling more effective locally — but this is a distinct mechanism from being, or replacing, growth hormone itself. Its primary and best-documented mechanism is angiogenic (VEGFR2-Akt-eNOS pathway), not endocrine [4]. Claims that BPC-157 raises growth hormone or testosterone levels are not supported by the published evidence and should be treated skeptically.

## Does BPC-157 work immediately?

There is no controlled human trial measuring how quickly BPC-157 produces an effect, so this question cannot be answered from the clinical literature. Rodent pharmacokinetic work found a very short elimination half-life — under 30 minutes — with modest intramuscular bioavailability and rapid breakdown into small peptide fragments [3], meaning the compound itself clears the bloodstream quickly regardless of any downstream biological effect. Research-use community reports describe tendon, ligament, and joint improvements emerging over one to three weeks rather than immediately, but these are anecdotal, not clinical evidence, and are not backed by a controlled human timeline study.

## Does BPC-157 damage the liver?

The only human safety data available — a first-in-human pilot of intravenous BPC-157 up to 20 mg in two adults — found no measurable changes in hepatic (liver) biomarkers, alongside no changes in cardiac, renal, thyroid, or glucose markers [1]. This is a two-person pilot study, not a large-scale liver-safety trial, so it cannot rule out rare or long-term effects. A 2025 narrative review notes that rigorous large-scale human trials are lacking overall and recommends treating BPC-157 as investigational [2]. No published evidence currently shows liver damage from BPC-157, but the human safety dataset is too small to consider the question definitively settled.

## What does a GHK-Cu peptide do?

GHK-Cu is a copper-binding tripeptide that acts as a copper chaperone and a matrix-remodeling signal. At picomolar-to-nanomolar concentrations it stimulates dermal fibroblasts to produce collagen, elastin, glycosaminoglycans, and the proteoglycan decorin, while rebalancing matrix metalloproteinases against their inhibitors [11]. Gene-expression analysis reports that GHK modulates roughly 31.2% of human genes at a 50%-or-greater change threshold, upregulating wound-repair, DNA-repair, and antioxidant pathways [9]. Topically, this translates into documented improvements in skin firmness, wrinkle depth, and — in a controlled 45-person trial of a related formulation — hair density [10].

## What is the difference between GHK and GHK-Cu?

GHK is the plain tripeptide glycyl-L-histidyl-L-lysine on its own. GHK-Cu is the same tripeptide chelated to a copper(II) ion. The distinction matters because copper coordination is required for most of the compound's documented tissue-remodeling activity — the copper enables lysyl-oxidase-mediated collagen cross-linking and gives the molecule its antioxidant, superoxide-dismutase-like activity [9][11]. Products or literature describing GHK and GHK-Cu interchangeably can be misleading; the copper-bound form is what the cosmetic and research literature on skin and hair effects actually describes.

## Is GHK-Cu peptide really anti-aging?

GHK-Cu has genuine, controlled human evidence for topical anti-aging effects, though the term anti-aging is broader than what has been tested. A 2025 review found that topical GHK-Cu increased procollagen synthesis in 70% of treated subjects, versus 50% for vitamin C and 40% for retinoic acid, in the trials it reviewed [8]. A separate review documents placebo-controlled improvements in skin laxity, clarity, fine-line depth, and wrinkle density [11]. Plasma GHK levels naturally decline with age — from roughly 200 ng/mL at 20 to about 80 ng/mL by 60 [11] — part of the rationale for topical replacement, though restoring a youthful GHK level topically is not the same claim as reversing aging generally.

## What is GLOW peptide?

GLOW is a research-community name for a co-formulated combination, most commonly GHK-Cu, BPC-157, and TB-500, marketed for skin renewal alongside tissue repair. A commonly cited research-label ratio is 10 mg BPC-157 / 10 mg TB-500 / 50 mg GHK-Cu, though exact ratios vary by supplier. There is no FDA-approved GLOW product, and no controlled study has tested the three-peptide combination itself — a 2026 review is the closest peer-reviewed source discussing all three named constituents, and it does not test or endorse combining them [13].

## What peptides are in the GLOW blend?

The GLOW blend most commonly combines three peptides: GHK-Cu (a copper-binding tripeptide studied for collagen and matrix remodeling), BPC-157 (a pentadecapeptide studied for angiogenesis and cytoprotection), and TB-500 (a synthetic fragment of thymosin beta-4 studied for cell migration and tissue repair). Each has its own independent research literature; none has been studied as a three-way combination in a controlled trial [13].

## What is the Wolverine peptide blend?

Wolverine is a research-community name for a two-peptide pairing of BPC-157 and TB-500, without the GHK-Cu skin-focused component found in GLOW. It is marketed specifically for tendon, ligament, and soft-tissue-injury recovery. As with GLOW, there is no controlled study of the two peptides given together — a 2025 systematic review of BPC-157 in sports medicine (36 studies, only one in humans) makes no mention of TB-500 or any combination use [15].

## Why are BPC-157 and TB-500 combined (the Wolverine stack)?

The rationale is mechanistic complementarity: BPC-157 is studied primarily for angiogenesis (new blood-vessel growth) via the VEGFR2-Akt-eNOS pathway [4], while TB-500 — the synthetic fragment of thymosin beta-4 — is studied for actin-binding and cell-migration effects that support re-epithelialization and progenitor-cell mobilization [16]. The theory is that a vascular signal and a cell-mobility signal, acting on largely separate pathways, might support recovery from different angles. This is an extrapolation from each peptide's independently characterized mechanism — no controlled combination study has confirmed a synergistic effect, dose, or ratio.

## Are these four compounds safe?

Safe is not a single answer across four compounds at very different evidence stages. GHK-Cu has a genuine, decades-long topical cosmetic safety record, but injectable or systemic use is unstudied in humans. BPC-157's only human data is a two-person intravenous safety pilot with no adverse events [1], alongside a review noting that large-scale rigorous trials are lacking [2]. GLOW and Wolverine are untested combinations: no study has evaluated the safety of either blend as formulated, and both include TB-500, a constituent that is prohibited in competitive sport by the World Anti-Doping Agency. All four are sold as research chemicals rather than approved medicines, meaning product identity and purity are not independently verified outside formal studies [13]. This desk reports these findings factually; it does not advise on safety for any individual, which requires a licensed clinician.

---

A clinician's-briefing digest on tissue-repair research peptides — read it for citations, not for a treatment plan.